An eNAMPT-neutralizing mAb reduces post-infarct myocardial fibrosis and left ventricular dysfunction.
Liu Z, Sammani S, Barber CJ, Kempf CL, Li F, Yang Z, Bermudez RT, Camp SM, Herndon VR, Furenlid LR, Martin DR, Garcia JGN.
Liu Z, et al. Among authors: martin dr.
Biomed Pharmacother. 2024 Jan;170:116103. doi: 10.1016/j.biopha.2023.116103. Epub 2023 Dec 30.
Biomed Pharmacother. 2024.
PMID: 38160623
Free PMC article.